Evidence map›Paper›PMID 26026991›Full record

Observational studyClinical and experimental nephrology2016

Prevalence of gastroesophageal reflux disease symptoms and effects of esomeprazole on the quality of life related to reflux and dyspepsia in patients on maintenance hemodialysis.

Tamehachi Namikoshi, Kazuhiro Harada, Hidekazu Hatta, Takehiko Tokura, Yoshiyuki Oshiro, Tetsuichi Nishizaki, Takahiro Obata, Masahiro Mori, Takaaki Fueki, Sohachi Fujimoto and 10 more

Abstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Clinical and experimental nephrology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 1 country.

Tamehachi NamikoshiDepartment of Nephrology and Hypertension, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Japan. tnamikoshi@med.kawasaki-m.ac.jp.
Kazuhiro HaradaDepartment of Internal Medicine, Kasaoka Daiichi Hospital, Kasaoka, Japan.
Hidekazu HattaDepartment of Internal Medicine, Satou Memorial Hospital, Shoo, Japan.
Takehiko TokuraDepartment of Internal Medicine, Fukuyama City Hospital, Fukuyama, Japan.
Yoshiyuki OshiroDepartment of General Internal Medicine 1, Kawasaki Medical School, Kurashiki, Japan.
Tetsuichi NishizakiNishizaki Internal Medicine Clinic, Kurashiki, Japan.
Takahiro ObataObata Medicine Clinic, Tsuyama, Japan.
Masahiro MoriSanyo Nephro Clinic, Fukuyama, Japan.
Takaaki FuekiFueki Naika Clinic, Okayama, Japan.
Sohachi FujimotoDepartment of Nephrology and Hypertension, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Japan.
Yoshisuke HarunaDepartment of Nephrology and Hypertension, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Japan.
Atsunori KuwabaraDepartment of Nephrology and Hypertension, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Japan.
Daisuke YorimitsuDepartment of Nephrology and Hypertension, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Japan.
Chieko IhoriyaDepartment of Nephrology and Hypertension, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Japan.
Hiroyuki KadoyaDepartment of Nephrology and Hypertension, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Japan.
Seiji ItanoDepartment of Nephrology and Hypertension, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Japan.
Yasuo FujimotoDepartment of Nephrology and Hypertension, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Japan.
Norio KomaiDepartment of Nephrology and Hypertension, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Japan.
Tamaki SasakiDepartment of Nephrology and Hypertension, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Japan.
Naoki KashiharaDepartment of Nephrology and Hypertension, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Japan.
Kawasaki Medical School · JPAkebono Clinic · JPFukuyama City Hospital · JPNational Sanyo Hospital · JPSatou Hospital · JPTsuyama Chuo Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe prevalence of gastroesophageal reflux disease (GERD) symptoms has not been investigated in patients on maintenance hemodialysis in Japan, and few studies have reported the effect of proton pump inhibitors (PPIs) in hemodialysis patients with GERD symptoms. Here, we investigated the prevalence of GERD symptoms and the effects of the PPI esomeprazole on the quality of life related to reflux and dyspepsia in patients on maintenance hemodialysis.

methodsThis was a cross-sectional/cohort study of hemodialysis outpatients implemented in 10 Japanese medical facilities from October 2012 to March 2014. The trial was registered in the UMIN Clinical Trial Registry (UMIN000009124).

resultsForty-one of 385 patients (11%) reported GERD symptoms on the Global Overall Symptom (GOS) questionnaire. Multivariate logistic regression analysis identified the independent prognostic factors for GERD symptoms as a history of gastric ulcer and use of sevelamer hydrochloride or calcium polystyrene sulfonate. Participants with GERD symptoms completed the Quality of Life in Reflux and Dyspepsia, Japanese version (QOLRAD-J) questionnaire and were assigned to receive 4-week esomeprazole treatment (20 mg/day). This PPI therapy significantly improved all QOLRAD-J domains in the full analysis set (n = 28) and improved the GERD symptoms listed in the GOS questionnaire. Significantly impaired disease-specific quality of life (QOL) in the QOLRAD-J domains was observed in 44.4-74.1% of patients who had symptoms before treatment. The mean GOS and QOLRAD-J scores correlated significantly.

conclusionTherapy with 20 mg/day esomeprazole appears to be efficacious for improving disease-specific QOL and GERD symptoms in Japanese patients on maintenance hemodialysis.

Indexed as

Quality of LifeRenal DialysisAdultAgedAged, 80 and overCross-Sectional StudiesDyspepsiaEsomeprazoleFemaleGastroesophageal RefluxHumansJapanKidney DiseasesLogistic ModelsMaleMiddle AgedEsomeprazoleProton Pump InhibitorsGastroesophageal reflux diseaseHemodialysisProton pump inhibitorsQuality of lifeQuestionnaires

Identifiers

PMID26026991
OpenAlexW425083356

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.